Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Protein Complexes with Interchangeable Parts

Protein Complexes with Interchangeable Parts

Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...

Protein Complexes with Interchangeable Parts

Protein Complexes with Interchangeable Parts

Expected Value

Expected Value

The expected value is known as the "long-term" average or mean. This means that over the long term of experimenting over and over, you would expect this average. The expected average is represented by the symbol μ. It is calculated as follows:

Determination of Expected Frequency

Determination of Expected Frequency

Suppose one wants to test independence between the two variables of a contingency table. The values in the table constitute the observed frequencies of the dataset. But how does one determine the expected frequency of the dataset? One of the important assumptions is that the two variables are independent, which means the variables do not influence each other. For independent variables, the statistical probability of any event involving both variables is calculated by multiplying the individual...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Different Clinical Questions Need Different Estimands.

Therapeutic innovation & regulatory science·2026

Same journal

Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.

Therapeutic innovation & regulatory science·2026

Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026

Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026

Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026

Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 11, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

FDA Expectations for Demonstrating Interchangeability.

Kamali Chance¹

¹1 CEO & Executive Consultant, KC Biopharma Consulting LLC, Graham, NC, USA.

Therapeutic Innovation & Regulatory Science

|May 2, 2018

Summary

This summary is machine-generated.

Companies developing biosimilars seek interchangeability designation in the US for pharmacy-level substitution. This designation offers 12 months of marketing exclusivity for the first approved sponsor.

Keywords:

FDA biosimilar interchangeability interchangeable marketing exclusivity

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

Related Experiment Videos

Last Updated: Feb 11, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

Area of Science:

Biopharmaceutical development
Regulatory science
Pharmacology

Background:

Global companies are developing biosimilars for US market entry.
Interchangeability designation is crucial for biosimilar commercialization.
This designation enables pharmacy-level substitution without healthcare provider intervention.

Purpose of the Study:

To outline the US Food and Drug Administration's (FDA) expectations for demonstrating biosimilar interchangeability.
To provide insights into the regulatory pathway for achieving interchangeability designation.
To inform biosimilar developers about key requirements for commercial success.

Main Methods:

Review of current FDA guidance and regulatory documents.
Analysis of scientific data requirements for interchangeability studies.
Synthesis of expert understanding regarding FDA's assessment criteria.

Main Results:

Interchangeability requires robust data demonstrating no clinically meaningful differences between the biosimilar and the reference product.
Specific study designs and endpoints are critical for FDA evaluation.
Successful demonstration of interchangeability leads to significant commercial advantages.

Conclusions:

Achieving interchangeability designation is a strategic imperative for biosimilar sponsors in the US.
Understanding and meeting FDA expectations for interchangeability data is paramount.
The designation offers substantial market benefits, including exclusivity and substitution.